Rannuo Biopharmaceutical Technology

Rannuo Biopharmaceutical is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of next-generation small molecule drugs. The company focuses on immunology, inflammation, and oncology, utilizing a proprietary platform to design highly selective kinase inhibitors. Its lead candidate, RN-001, is a potent and selective TYK2 inhibitor designed to treat autoimmune diseases such as psoriasis and lupus with improved safety profiles. Founded by industry veterans with extensive experience in global pharmaceutical companies, Rannuo aims to deliver innovative therapies for patients with significant unmet medical needs. The company's pipeline includes several programs targeting key pathways in immune-mediated diseases and cancer.